As the vaccine is hailed as the only cure for the SARS-CoV-2 pandemic, scientists and researchers are working round the clock to assure probable protection against the virus. Scientists from Utrecht University in the Netherlands, as well as the Erasmus Medical Centre and the company Harbour BioMed (HBM), have identified a potential method of neutralizing COVID-19.
Covid-19 has affected over 200 countries and 3,757,469 people. It has claimed over 259,496 lives worldwide and continues to ravage the world as we know it. Utrecht University, along with the partners, found in their study that the antibody which prevents the SARS virus has the capability to stop the Covid-19.
“This research builds on the work our groups have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003,” said Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the Nature Communications study.
“Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes the Infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has the potential to alter the course of Infection in the infected host, support virus clearance, or protect an uninfected individual that is exposed to the virus.”
The discovery is a huge leap forwards in the theory and treatment, which is based on antibody collection from formerly treated patients of coronavirus. The human trial phase is expected to begin soon as “this discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment,” said Frank Grosveld, PhD co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed.
“The antibody used in this work is ‘fully human,’ allowing development to proceed more rapidly and reducing the potential for immune-related side effects.” Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to ‘humanize’ them. The antibody was generated using Harbour BioMed’s H2L2 transgenic mouse technology.
The paper titled A human monoclonal antibody blocking SARS-VoV-2 Infection is expected to provide new dawn in the medical research of the Covid-19’s cure. “The groundbreaking research” will open new avenues for other possible tests to follow. The antibody was generated using Harbour BioMed’s H2L2 transgenic mouse technology. “We believe our technology can contribute to addressing this most urgent public health need, and we are pursuing several other research avenues,” said Dr Jingsong Wang.